AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent

AnPac Bio-Medical Science Co Ltd ANPC has received its first disease treatment patent by the United States Patent and Trademark Office.
The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.
The patent covers novel device structures and methods to modify biological samples for treatment purposes. This latest patent is the 21st patent granted to AnPac Bio in the U.S.
The Company also announced that its newly launched cancer treatment joint venture has secured, via signed legal documents, over $4 million of capital contributions from multiple funding sources.
The funding will be used to fabricate cancer treatment medical devices and the device's subsequent laboratory tests this year.
Price Action: ANPC shares are up 21.9% at $5.29 during the premarket trading session on the last check Friday.